The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study - Guy M. Goodwin; Lindsey Marwood; S. Mistry; Anna Nowakowska; Zainib Shabir; H. Clifton Simmons; E.K. Teoh; Jeng-Yu Tsai; E. Malievskaia (Neuroscience Applied, 2022)

Effect of co-administration of low doses of psilocybin and mGluR2/3 antagonist LY341495 in chronic restraint stress model of depression - Agata Machaczka; Jane Turek; Dorota Bederska-Łojewska; Bartłomiej Pochwat; Łukasz Gąsior; Bernadeta Szewczyk; Andrzej Pilc (Neuroscience Applied, 2022)

Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice - Sofia Nasini; Martina Colognesi; Sara Tidei; Sara De Martin; Marco Banzato; Andrea Mattarei; Franco Folli; P. Marco; Paolo L. Manfredi; Stefano Comai (Neuroscience Applied, 2022)

Withdrawal of antidepressants does not impact the efficacy of COMP360 psilocybin therapy: results from a phase IIb randomised controlled trial - Guy M. Goodwin; Megan Croal; J. Chai-Rees; Lindsey Marwood; S. Mistry; Anna Nowakowska; H. Clifton Simmons; Jeng-Yu Tsai (Neuroscience Applied, 2022)

Change in whole blood BDNF after escitalopram or psilocybin intervention in patients with depression and healthy controls - Miriam L. Navarro; Alberte Wollesen Breum; Annette Johansen; Brice Ozenne; Vibe G. Frøkjær; Gitte M. Knudsen (Neuroscience Applied, 2022)

A multi-metric evaluation of psilocybin effects on functional brain entropy in healthy volunteers - Drummond E-Wen McCulloch; Anders Smærup Olsen; Dea Siggaard Stenbæk; Sophia Armand; M. Madsen; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2022)

Investigating changes in EEG entropy rate in response to psilocybin - a comparison of lempel ziv and state-space entropy rate measures - M. Nikolič; P. Mediano; Tom Froese; Tomáš Páleníček (Neuroscience Applied, 2022)

Visualizing drug actions on dendrites: psilocybin and other classic psychedelics - Ling-Xiao Shao; Clara Liao; Ian Gregg; Pasha A. Davoudian; Neil K. Savalia; Kristina Delagarza; Alex C. Kwan (2022)

Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data - Peter Hess (The Transmitter, 2022)

Company on brink takes psilocybin to trial for fragile X syndrome - Peter Hess (The Transmitter, 2022)

Therapeutic mechanism of psilocybin in the treatment of depression and other psychiatric disorders. - O. Shahar; A. Botvinik; T. Lifschytz; B. Lerer (Neuroscience Applied, 2022)

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses - Peter Hess (The Transmitter, 2022)

Ego Birth: Measure 109, The NMHA, and Forward Movement in the Nascent Psilocybin Industry - Andrew M. Robie (SSRN Electronic Journal, 2022)

The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa - Sebastian William Foster (Law Democracy & Development, 2022)

Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up results - Hannah Douglass; Merle Spriggs; Kate Godfrey; Jennifer L. Danby; Francisco Magalhães; Kirsty L. Alderton; Liane Macdonald; Stephanie Archer; Tim Read; Adèle Lafrance; Dasha Nicholls; David Erritzøe; et al. (Neuroscience Applied, 2022)

Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use - Brian S. Barnett; Noah Wiles Sweat; Peter S. Hendricks (Drug Science Policy and Law, 2022)

From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia - Octavian Dixon Ritchie; Cameron N Donley; Gabrielle Dixon Ritchie (Drug Science Policy and Law, 2022)

Electrophysiological study of visual and auditory processing in psilocin-induced hallucinations: exploring evoked potentials and 5-HT2A receptor involvement - Vejmola Č.; Hubený J.; Koudelka V.; Griškova-Bulanova I.; Páleníček T. (Neuroscience Applied, 2022)

Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. - Simonsson O; Goldberg SB (Journal of psychoactive drugs, 2022)

The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. - Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S (Journal of psychoactive drugs, 2022)

Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. - Kious B; Schwartz Z; Lewis B (Journal of psychopharmacology (Oxford, England), 2022)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness - Matthias Forstmann; Hannes Kettner; Christina Sagioglou; Alexander Irvine; Sam Gandy; Robin Carhart-Harris; David Luke (Journal of Psychopharmacology, 2022)

Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models. - Ezeaka UC; Kim HJJ; Laprairie RB. (2022)

Functional MRI markers for treatment-resistant depression: Insights and challenges. - Kotoula V; Evans JW; Punturieri C; Johnson SC; Zarate CA (Progress in brain research, 2022)

The Resurgence of Hallucinogen Drugs in Clinical Research. - Rivera-García MT; Cruz SL. (2022)

UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. - Ahmed H; Mushahid H; Arshad T. (2022)

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression - Natalie Gukasyan (Med, 2022)

Is psilocybin an effective antidepressant and what is its Mechanism of action? - Mann JJ. (2022)

Editorial: What is up with psychedelics anyway? - Lewis CR; McMurray M; Mennenga SE; Helms Tillery S (Frontiers in neuroscience, 2022)

Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders. - Vorobyeva N; Kozlova AA (Frontiers in pharmacology, 2022)

Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. - Shaw L; Rea K; Lachowsky NJ; Roth EA (Journal of psychoactive drugs, 2022)

Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users. - Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P (Journal of psychoactive drugs, 2022)

Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. - Kelly JR; Clarke G; Harkin A; Corr SC; Galvin S; Pradeep V; Cryan JF; O'Keane V; Dinan TG (International journal of clinical and health psychology: IJCHP, 2022)

The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials. - IsHak WW; Garcia P; Pearl R; Dang J; William C; Totlani J; Danovitch I. (2022)

Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. - Rankaduwa S; Owen AM (Neuroscience of consciousness, 2022)

Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. - Mosurinjohn S; Roseman L; Girn M (Frontiers in psychiatry, 2022)

Mini-review: The neurobiology of treating substance use disorders with classical psychedelics. - Urban MM; Stingl MR; Meinhardt MW (Frontiers in neuroscience, 2022)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders. - Blest-Hopley G; Amit BH; O'Neill A; Ruffell SGD (Frontiers in psychiatry, 2022)

Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. - Phan AN; Terry GE (Frontiers in psychiatry, 2022)

Medical student attitudes and perceptions of psychedelic-assisted therapies. - Li I; Fong R; Hagen M; Tabaac B (Frontiers in psychiatry, 2022)

Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. - Blond BN; Schindler EAD (Frontiers in neurology, 2022)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. - Hartong V; van Emmerik A (Journal of psychoactive drugs, 2022)

What is the progress of experimental drug development for fibromyalgia? - Lawson K (Expert opinion on investigational drugs, 2022)

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development. - Simonsson O; Stenfors CUD; Goldberg SB; Hendricks PS; Osika W (Frontiers in psychology, 2022)

The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness. - Longo MSC; Bienemann B; Multedo M; Negreiros MA; Schenberg E; Mograbi DC (Journal of psychoactive drugs, 2022)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. - Herrmann Z; Earleywine M; De Leo J; Slabaugh S; Kenny T; Rush AJ (Journal of psychoactive drugs, 2022)

An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically. - Kruger DJ; Glynos NG; Fields CW; Herberholz M; Boehnke KF (Journal of psychoactive drugs, 2022)

Bedside to bench: the outlook for psychedelic research. - Acero VP; Cribas ES; Browne KD; Rivellini O; Burrell JC; O'Donnell JC; Das S; Cullen DK (Frontiers in pharmacology, 2022)

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. - Barnett BS; Bassir Nia A; Sackett NB; Weleff J (Frontiers in psychiatry, 2022)

"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics. - Kruger DJ; Enghoff O; Herberholz M; Barron J; Boehnke KF (Journal of psychoactive drugs, 2022)

Psychedelics, epilepsy, and seizures: a review. - Freidel N; Kreuder L; Rabinovitch BS; Chen FY; Huang RST; Lewis EC (Frontiers in pharmacology, 2022)

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? - Antonio Munafò; Davide Arillotta; Guido Mannaioni; Fabrizio Schifano; Renato Bernardini; Giuseppina Cantarella (Pharmaceuticals, 2022)

Genome sequencing progenies of magic mushrooms (Psilocybe subaeruginosa) identifies tetrapolar mating and gene duplications in the psilocybin pathway - Alistair R. McTaggart; Timothy Y. James; Jason C. Slot; Caine Barlow; Nigel Fechner; Louise S. Shuey; A. Drenth (Fungal Genetics and Biology, 2022)

The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions - Vanessa Eveline VLAIC; Andreea ONA (Hop and Medicinal Plants, 2022)

A Review of Synthetic Access to Therapeutic Compounds Extracted from. - Serreau R; Amirouche A; Benyamina A; Berteina-Raboin S (Pharmaceuticals (Basel, Switzerland), 2022)

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial - Robin von Rotz; Eva Maria Schindowski; Johannes Jungwirth; Anna Schuldt; Nathalie M. Rieser; Katharina Zahoranszky; Erich Seifritz; Albina Nowak; Peter J.C.M. Nowak; Lutz Jäncke; Katrin H. Preller; Franz X. Vollenweider (EClinicalMedicine, 2022)

High dose of psilocybin effective for treatment-resistant depression (The Brown University Psychopharmacology Update, 2022)

Canalization and plasticity in psychopathology. - Carhart-Harris RL; Chandaria S; Erritzoe DE; Gazzaley A; Girn M; Kettner H; Mediano PAM; Nutt DJ; Rosas FE; Roseman L; Timmermann C; Weiss B; et al. (2022)

Depression Improves Following Single Dose of Psilocybin - Nick Zagorski (Psychiatric News, 2022)

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. - Meccia J; Lopez J; Bagot RC. (2022)

The varieties of psychedelic law. - Marks M. (2022)

Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment - Priel Meir; Leslie Taylor; Jair C. Soares; Thomas D. Meyer (Journal of Affective Disorders, 2022)

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. - Heal DJ; Gosden J; Smith SL; Atterwill CK. (2022)

Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster - Bradshaw AJ; Ramírez-Cruz V; Awan AR; Furci G; Guzmán-Dávalos L; Stamets P; Dentinger BT. (bioRxiv, 2022)

“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use - Meghan DellaCrosse; Mollie Pleet; Emma Morton; Amir Ashtari; Kimberly Sakai; Josh Woolley; Erin E. Michalak (PLoS ONE, 2022)

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption - Emma Morton; Kimberly Sakai; Amir Ashtari; Mollie Pleet; Erin E. Michalak; Josh Woolley (Journal of Psychopharmacology, 2022)

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants - Friederike Holze; A. Becker; Karolina E. Kolaczynska; Urs Duthaler; Matthias E. Liechti (Clinical Pharmacology & Therapeutics, 2022)

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients - Sarah Shnayder; Rezvan Ameli; Ninet Sinaii; Ann Berger; Manish Agrawal (Journal of Affective Disorders, 2022)

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. - Kelly DF; Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ. (2022)

Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum - Geoffrey M. Bove; David J. Mokler (Journal of Psychedelic Studies, 2022)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation - Daniel Burmester; M. Madsen; Attila Szabó; Sanjay S. Aripaka; Dea Siggaard Stenbæk; Vibe G. Frøkjær; Betina Elfving; Jens D. Mikkelsen; Gitte M. Knudsen; Patrick M. Fisher (Comprehensive Psychoneuroendocrinology, 2022)

Update on treatments for anxiety-related disorders. - Lee HJ; Stein MB. (2022)

Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome - Valeria Buzzelli; Emilia Carbone; Antonia Manduca; Sara Schiavi; Alessandro Feo; Julia V. Perederiy; Kyle Ambert; M Hausman; Viviana Trezza (Psychopharmacology, 2022)

Lower-dose psycholytic therapy - A neglected approach. - Passie T; Guss J; Krähenmann R. (2022)

Matrix-assisted laser-desorption/ionization-mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate - Hang Wang; Ying Wang (Analytical and Bioanalytical Chemistry, 2022)

Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens - Prokopios Magiatis; Evangelos Dadiotis; Romanos Konstantinos Antonopoulos; K Ioannidis; V Mitsis; E Melliou; Zacharoula Gonou-Zagou (Planta Medica, 2022)

Set and setting in microdosing: an oft-overlooked principle. - Hartogsohn I; Petranker R (Psychopharmacology, 2022)

Psychedelic-Assisted Therapy for People with Eating Disorders. - Gukasyan N; Schreyer CC; Griffiths RR; Guarda AS (Current psychiatry reports, 2022)

A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability - Gregory Barber; Charles B. Nemeroff; Steven Siegel (American Journal of Psychiatry, 2022)

Therapeutic use of psilocybin: Practical considerations for dosing and administration. - MacCallum CA; Lo LA; Pistawka CA; Deol JK. (2022)

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report - Benjamin Kelmendi; Stephen A. Kichuk; Giuliana DePalmer; Gayle Maloney; Terence H. W. Ching; Alexander Belser; Christopher Pittenger (Heliyon, 2022)

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites - Alexander J. Bradshaw; Talia Backman; Virginia Ramírez-Cruz; Dale L. Forrister; Jaclyn M. Winter; Laura Guzmán-Dávalos; Giuliana Furci; Paul Stamets; Bryn T. M. Dentinger (Applied and Environmental Microbiology, 2022)

Antidepressant properties of psilocybin might be related to changes in sleep - Marten Dooper (2022)

Fast and sustained effect of 2 administrations of psilocybin on depression - Marten Dooper (2022)

Mode of action of psilocybin - Marten Dooper (2022)

Considerations in assessing the abuse potential of psychedelics during drug development. - Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D. (2022)

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. - Shukuroglou M; Roseman L; Wall M; Nutt D; Kaelen M; Carhart-Harris R. (Journal of Psychopharmacology, 2022)

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. - Schindler EAD; Sewell RA; Gottschalk CH; Luddy C; Flynn LT; Zhu Y; Lindsey H; Pittman BP; Cozzi NV; D'Souza DC. (Headache The Journal of Head and Face Pain, 2022)

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. - Irizarry R; Winczura A; Dimassi O; Dhillon N; Minhas A; Larice J. (2022)

Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis. - Schäfer T; Kramer K; Werten S; Rupp B; Hoffmeister D. (ChemBioChem, 2022)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. - Messell C; Summer L; Bonde LO; Beck BD; Stenbæk DS. (Frontiers in Psychology, 2022)

NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System. - NWTraumatherapies (ClinicalTrials.gov, 2022)

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. - Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Lotan A; Wolf G; Lerer B; Lifschytz T. (International Journal of Molecular Sciences, 2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine - Guss J; Krause R; Sloshower J. (PsyArXiv, 2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine (PsyArXiv, 2022)

Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism - Schmitz GP; Chiu Y; König GM; Kostenis E; Roth BL; Herman MA. (bioRxiv, 2022)

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids. - Gotvaldová K; Borovička J; Hájková K; Cihlářová P; Rockefeller A; Kuchař M. (International Journal of Molecular Sciences, 2022)

Body mass index (BMI) does not predict responses to psilocybin. - Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL. (Journal of Psychopharmacology, 2022)

Chlorothiazide/paracetamol/psilocybin (Reactions Weekly, 2022)

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence - NYU Langone Health (ClinicalTrials.gov, 2022)

Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. - Strauss D; Ghosh S; Murray Z; Gryzenhout M. (2022)

Psilocin - The "real deal" or an extraction byproduct. - Gutman O; Tenne D; Bretler U. (2022)

Psilocybin-assisted therapy reduces heavy drinking in patients with AUD (The Brown University Psychopharmacology Update, 2022)

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice - Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC. (bioRxiv, 2022)

The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. - VanderZwaag J; Halvorson T; Dolhan K; Šimončičová E; Ben-Azu B; Tremblay MÈ. (2022)

Psilocybin reduces symptoms in treatment resistant depression, trial results show. - Iacobucci G. (BMJ, 2022)

Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. - Glatfelter GC; Pottie E; Partilla JS; Sherwood AM; Kaylo K; Pham DNK; Naeem M; Sammeta VR; DeBoer S; Golen JA; Hulley EB; Stove CP; et al. (ACS Pharmacology & Translational Science, 2022)

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. - O'Donnell KC; Mennenga SE; Owens LT; Podrebarac SK; Baron T; Rotrosen J; Ross S; Forcehimes AA; Bogenschutz MP. (Contemporary Clinical Trials, 2022)

The psychedelic renaissance: can psilocybin possibly combat depression? - Hamna Raheel; Unaiza Naeem; Asim Shaikh; Omer Ahmed Shaikh (International Journal of Surgery Global Health, 2022)

A Rare Case of Magic Mushroom (Psilocybin) Related AKI and Hypertensive Emergency - Syed Rizwan A. Bokhari; Ahmad Makmom Abdullah; Zamir A. Zamir; Raquel M. Rosen (Journal of the American Society of Nephrology, 2022)

Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers - Mason N; Szabo A; Kuypers K; Mallaroni P; de la Torre Fornell R; Reckweg J; Tse D; Hutten N; Feilding A; Ramaekers J. (medRxiv, 2022)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. - Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA. (2022)

Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer. - Patchett-Marble R; O'Sullivan S; Tadwalkar S; Hapke E. (Canadian Family Physician, 2022)

[Treatment-resistant depression. From classification to new therapies.] - Paganin W; Signorini S; Signorini S; Leccese V; Sciarretta A. (Rivista di psichiatria, 2022)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. - Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; et al. (New England Journal of Medicine, 2022)

Psilocybin in Treatment-Resistant Depression. - Madras BK. (2022)

Microdosing with classical psychedelics: Research trajectories and practical considerations. - Wong A; Raz A. (2022)

Five new species of Inosperma from China: Morphological characteristics, phylogenetic analyses, and toxin detection. - Li SN; Xu F; Long P; Liu F; Zhang P; Fan YG; Chen ZH. (Frontiers in Microbiology, 2022)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. - Jones GM. (Journal of Psychopharmacology, 2022)

Kan psilocybin forbedre vores moral? - Victor Lange; Marie; Sidsel (Research at the University of Copenhagen (University of Copenhagen), 2022)

What Are Magic Mushrooms? Why They Are Popular In British Columbia - b2xvysw192 (Zenodo (CERN European Organization for Nuclear Research), 2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects - Gukasyan N; Griffiths RR; Yaden DB; Antoine D; Nayak SM. (PsyArXiv, 2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. - Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R. (Psychedelic Medicine, 2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects (PsyArXiv, 2022)

Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects. - Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM. (NeuroImage, 2022)

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. - Sheppard Pratt Health System (ClinicalTrials.gov, 2022)

Electrical spiking of psilocybin fungi. - Gandia A; Adamatzky A. (Communicative & Integrative Biology, 2022)

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial (PsyArXiv, 2022)

Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? - Dupuis D; Veissière S. (2022)

Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression. - Balon R. (2022)

Psilocybin treatment for AUD: Promise in new study - Alison Knopf (Alcoholism & Drug Abuse Weekly, 2022)

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). - Jensen ME; Jensen ME; Stenbæk DS; Juul TS; Fisher PM; Ekstrøm CT; Knudsen GM; Fink-Jensen A. (BMJ Open, 2022)

Mescaline: The forgotten psychedelic. - Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ. (2022)

An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) - Beckley Psytech Limited (ClinicalTrials.gov, 2022)

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. - Sottile RJ; Vida T. (2022)

Potential Therapeutic Effects of Psilocybin: A Systematic Review. - Goel DB; Zilate S. (2022)

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. - Weleff J; Akiki TJ; Barnett BS. (Journal of Psychoactive Drugs, 2022)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. - Jones GM; Nock MK. (Scientific Reports, 2022)

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. - Ko K; Kopra EI; Cleare AJ; Rucker JJ. (2022)

Psilocybin: a revolution in psychedelic medicines in the US? - Silberner J. (BMJ, 2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 - Ching THW; Kichuk S; DePalmer G; Pittenger C; Kelmendi B. (PsyArXiv, 2022)

Predictors of Psychedelic Experience: A Thematic Analysis. - McCartney AM; McGovern HT; De Foe A. (Journal of Psychoactive Drugs, 2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 (PsyArXiv, 2022)

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. - Søndergaard A; Madsen MK; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (Frontiers in Psychology, 2022)

Conformational Landscape and Properties of Psilocybin: A Computational Approach - Poonam Bhadoria; V. Ramanathan (ChemistrySelect, 2022)

Chinese Cordyceps: Bioactive Components, Antitumor Effects and Underlying Mechanism-A Review. - Liu Y; Guo ZJ; Zhou XW (Molecules (Basel, Switzerland), 2022)

Group Format Psilocybin-Assisted Therapy: Commentary on the HOPE trial (HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer) - Benjamin R. Lewis; Kevin Byrne; Anna C. Beck (Journal of Anesthesiology and Pain Therapy, 2022)

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. - Singleton SP; Luppi AI; Carhart-Harris RL; Cruzat J; Roseman L; Nutt DJ; Deco G; Kringelbach ML; Stamatakis EA; Kuceyeski A. (Nature Communications, 2022)

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. - López-Arnau R; Camarasa J; Carbó ML; Nadal-Gratacós N; Puigseslloses P; Espinosa-Velasco M; Urquizu E; Escubedo E; Pubill D. (2022)

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. - Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI. (2022)

19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations - Natalie Gukasyan (Journal of the American Academy of Child & Adolescent Psychiatry, 2022)

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. - Timmermann C; Watts R; Dupuis D (Transcultural psychiatry, 2022)

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. - Dworkin RH; Anderson BT; Andrews N; Edwards RR; Grob CS; Ross S; Satterthwaite TD; Strain EC (The journal of pain, 2022)

Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. - Barnett BS; Ziegler K; Doblin R; Carlo AD (Journal of psychopharmacology (Oxford, England), 2022)

New investigational agents for the treatment of major depressive disorder. - Pochwat B; Krupa AJ; Siwek M; Szewczyk B (Expert opinion on investigational drugs, 2022)

Prevalence and associations of classic psychedelic-related seizures in a population-based sample. - Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS (Drug and alcohol dependence, 2022)

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. - Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; et al. (2022)

Expectancy in placebo-controlled trials of psychedelics: if so, so what? - Butler M; Jelen L; Rucker J (Psychopharmacology, 2022)

Why Otolaryngologists Should Be Interested in Psychedelic Medicine. - Asher BF (Otolaryngologic clinics of North America, 2022)

Animal Behavior in Psychedelic Research. - Odland AU; Kristensen JL; Andreasen JT. (2022)

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. - Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ (Transcultural psychiatry, 2022)

Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. - Cruzat J; Perl YS; Escrichs A; Vohryzek J; Timmermann C; Roseman L; Luppi AI; Ibañez A; Nutt D; Carhart-Harris R; Tagliazucchi E; Deco G; et al. (Network Neuroscience, 2022)

Psilocybin for Treatment of Alcohol Use Disorder. - Slomski A. (JAMA, 2022)

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier? - Mohamed A; Touheed S; Ahmed M; Hor M; Fatima S (Cureus, 2022)

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing - Dougherty RF; Clarke P; Alti M; Kuc J; Schlosser D; Dunlop BW; Hellerstein DJ; Aaronson ST; Zisook S; Young AH; Carhart-Harris R; Goodwin G; et al. (PsyArXiv, 2022)

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing (PsyArXiv, 2022)

The use of classic psychedelics among adults: a Danish online survey study. - Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A. (Nordic Journal of Psychiatry, 2022)

Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. - Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M. (2022)

Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP001 And COMP003 Trials (P-TRD LTFU) - COMPASS Pathways (ClinicalTrials.gov, 2022)

The Emerging Field of Psychedelic Psychotherapy. - Barber GS; Aaronson ST. (2022)

Brain dynamics predictive of response to psilocybin for treatment-resistant depression - Vohryzek J; Cabral J; Lord L; Fernandes H; Roseman L; Nutt D; Carhart-Harris R; Deco G; Kringelbach M. (Research Square, 2022)

Towards an understanding of psychedelic-induced neuroplasticity. - Calder AE; Hasler G. (2022)

Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives - A Computational Study - Gomathi Saminathan; Kavitha Kandasamy; Savitha Navaneethakrishnan; Mohana Ashokkumar; Brindha Veerappan; Krishnamoorthy Bellie Sundaram; G Aghajanian; G Marek; J.-C Bque; M Imad; L Mladenovic; J Gingrich; et al. (Letters in Applied NanoBioScience, 2022)

Psilocybin as a healer - Kavita Golia (Consciousness Spirituality & Transpersonal Psychology, 2022)

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. - Pouyan N; Halvaei Khankahdani Z; Younesi Sisi F; Lee Y; Rosenblat JD; Teopiz KM; Lui LMW; Subramaniapillai M; Lin K; Nasri F; Rodrigues N; Gill H; et al. (2022)

Neural mechanisms of psychedelic visual imagery - Stoliker D; Preller KH; Novelli L; Anticevic A; Egan GF; Vollenweider FX; Razi A. (medRxiv, 2022)

Effective connectivity of emotion and cognition under psilocybin - Stoliker D; Novelli L; Vollenweider FX; Egan GF; Preller KH; Razi A. (medRxiv, 2022)

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample. - Mellner C; Dahlen M; Simonsson O (International journal of environmental research and public health, 2022)

Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder - Lerer B; Singh S; Botvinnik A; Shahar O; Wolf G; Yakobi C; Saban M; Salama A; Lotan A; Lifschytz T. (Research Square, 2022)

Psilocybin therapy reduces heavy drinking. - O'Leary K. (Nature Medicine, 2022)

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. - Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R. (BJPsych Open, 2022)

Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. - Walsh CA; Livne O; Shmulewitz D; Stohl M; Hasin DS. (Addictive Behaviors Reports, 2022)

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. - Johnston CB; Mangini M; Grob C; Anderson B. (2022)

Microdosing psilocybin for chronic pain: a case series. - Lyes M; Yang KH; Castellanos J; Furnish T. (Pain, 2022)

P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications - Diana Dias da Silva; Andreia Machado Brito-da-Costa; Silveira Martins; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho (Toxicology Letters, 2022)

From neuroplasticity to psychoplasticity: Psilocybin may reverse personality disorders and political fanaticism - Henry A. Nasrallah (Current Psychiatry, 2022)

Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder - Rodrigues J; Nombora O; Ribeiro L. (2022)

Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions - Girala N. (2022)

Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop - National Academies of Sciences; Engineering; Medicine; Health; Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience; Nervous System Disorders. (National Academies Press (US), Washington (DC), 2022)

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms - Chue P; Andreiev A; Bucuci E; Els C; Chue J. (2022)

Interplay of hydrogen bonding in deciding the conformers of psilocin: Computational insights - Bhadoria P; Venkatnarayan R. (Authorea Preprints, 2022)

Association of Psilocybin Use in Adolescents with Major Depressive Episode - Shah K; Trivedi C; Kamrai D; Akbar M; Tankersley W. (2022)

P03-18 Simultaneous detection and quantification of psilocybin and psilocin by gas chromatography coupled to mass spectrometry (GC-MS) - Brito-da-Costa A.M.; Madureira-Carvalho A.; Dinis-Oliveira R.J.; Silva D. Dias da (Toxicology Letters, 2022)

[The use of psilocybin for treatment-resistant depression]. - Johannesdottir A; Sigurdsson E. (2022)

Use of psychedelics in the Czech Republic: results of recent population surveys. - Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V. (Central European Journal of Public Health, 2022)

Psychedelics for Alzheimer's Disease Palliative Care. - McManus KR; Patrick R; Striepe MI; Drury MJ; Ozonsi R; Forester BP; Weinberg MS (Advances in psychiatry and behavioral health, 2022)

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. - Kurtz JS; Patel NA; Gendreau JL; Yang C; Brown N; Bui N; Picton B; Harris M; Hatter M; Beyer R; Sahyouni R; Diaz-Aguilar LD; et al. (Cureus, 2022)

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder. - Christensen JA; Fipps DC; Bostwick JM. (Experimental and Clinical Psychopharmacology, 2022)

Psychedelic Psychiatry - Nutt D. (2022)

﻿ Pseudospermaarenarium (Inocybaceae), a new poisonous species from Eurasia, based on morphological, ecological, molecular and biochemical evidence. - Yan YY; Zhang YZ; Vauras J; Zhao LN; Fan YG; Li HJ; Xu F. (MycoKeys, 2022)